This review considers trastuzumab's mechanism of action and its clinical value. As shown in Panel A, the four members of the HER family are HER1, HER2, HER3, and HER4. There are receptor-specific ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

13 In ErbB2-positive xenograft models, lapatinib combined with trastuzumab resulted in stabilization of inactive ErbB2 receptor as a result of a mechanism of action attributed to lapatinib, followed ...

In breast cancer, HER2-targeted therapy with trastuzumab has gained significant attention, owing to the dramatic response observed in a subset of HER2-positive patients. The mechanisms of action ...

To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option At least five potential extracellular and intracellular antitumor mechanisms of ...

The manufacturer recommends an initial trastuzumab dose of 4 mg/kg i.v. over 90 minutes, followed by a weekly maintenance dose of 2 mg/kg i.v. administered over 30 minutes if the initial dose is ...

The efficacy of trastuzumab, both as a single agent ... Tremendous resources have been spent in efforts to elucidate the mechanisms of action, safety, optimal combination therapies and mechanisms ...

In general, trastuzumab therapy is well tolerated. The most common adverse events are infusion related -- primarily fever and chills -- and occur in approximately 40% of patients during the ...

The pharmacokinetics of trastuzumab are not well-known. The volume of distribution approximates serum volume (44 mL/kg). [54] The elimination route has not been clearly defined. In studies in ...

QOL scores for the primary functional domains (physical, social, and role functioning; fatigue; and global QOL) did not decrease in patients treated with single-agent trastuzumab, and there were ...